Results for tag: "HER2 Negative Breast Cancer"

HER2-negative breast cancer is a type of breast cancer that tests negative for the presence of the human epidermal growth factor receptor 2 (HER2) protein, which promotes the growth of cancer cells. In the women's health context, it is a major focus due to the distinct treatment approaches required compared to HER2-positive cases. Women with HER2-negative breast cancer typically do not respond to therapies that target the HER2 protein, necessitating alternative treatment strategies. The market for HER2-negative breast cancer includes a range of products and services, from diagnostics to therapeutics. It encompasses hormone receptor-positive (HR+) therapies where the cancer is driven by hormones, as well as triple-negative breast cancer (TNBC) treatments where the cancer lacks estrogen and progesterone receptors and does not overexpress HER2. Progress in this market is driven by the development of novel agents, combination therapies, and a better understanding of tumor biology to create personalized medicine approaches. Advances in genomics and biomarker research are also instrumental in shaping the therapeutic landscape for HER2-negative breast cancer. In the HER2-negative breast cancer therapeutic market, several pharmaceutical companies have a prominent presence. Key players include Pfizer, with its portfolio of breast cancer therapies, and Roche, which, despite being known for its HER2-positive breast cancer treatments, also offers options for HER2-negative cases. Merck has been contributing through its expansive cancer drug repertoire. AstraZeneca and Eli Lilly are also significant contributors, with various approved Show Less Read more